SCHEMBL3546174

SCHEMBL3546174

CN1CCN(c2ccc(F)c(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c2)CC1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 11/20 0.73
PRKCQ Q04759 11/20 0.73
PRKCB P05771 10/20 0.73
PRKCH P24723 10/20 0.73
PRKCD Q05655 10/20 0.73
PRKCE Q02156 9/20 0.73
JAK3 P52333 11/20 0.61
JAK1 P23458 5/20 0.61
JAK2 O60674 3/20 0.61
TYK2 P29597 2/20 0.61
GSK3B P49841 2/20 0.59
PDPK1 O15530 1/20 0.59
DYRK3 O43781 1/20 0.59
PRKD3 O94806 1/20 0.59
MAP4K4 O95819 1/20 0.59
ABL1 P00519 1/20 0.59
EGFR P00533 1/20 0.59
ERBB2 P04626 1/20 0.59
PRKCG P05129 1/20 0.59
FYN P06241 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3549510 0.88 PRKCA (0.73) PRKCAPRKCQPRKCBPRKCHPRKCD
SCHEMBL21583796 0.87 JAK3 (0.81) PRKCAPRKCQPRKCBPRKCHPRKCD
SCHEMBL3553175 0.85 PRKCH (0.64) PRKCAPRKCQPRKCBPRKCHPRKCD
SCHEMBL3555948 0.85 PRKCA (0.60) PRKCAPRKCQPRKCBPRKCHPRKCD
SCHEMBL22410995 0.84 PRKCH (1.00) PRKCAPRKCQPRKCBPRKCHPRKCD
SCHEMBL16471240 0.84 PRKCA (0.68) PRKCAPRKCQPRKCBPRKCHPRKCD
SCHEMBL3555443 0.84 JAK3 (0.76) PRKCAPRKCQPRKCBPRKCHPRKCD
SCHEMBL4359102 0.83 PRKCH (0.61) PRKCAPRKCQPRKCBPRKCHPRKCD
SCHEMBL3541246 0.82 PRKCA (0.66) PRKCAPRKCQPRKCBPRKCHPRKCD
SCHEMBL4077139 0.82 PRKCH (0.73) PRKCAPRKCQPRKCBPRKCHPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1747216-B1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2014-01-08 EP claimed
US-7851475-B2 Substituted pyrrole-2, 5-diones as protein kinase C inhibitors NOVARTIS AG (CH) 2010-12-14 US claimed
US-20090221605-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2009-09-03 US claimed
EP-1747216-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS Novartis Pharma AG. (CH) 2007-01-31 EP claimed
WO-2005113545-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2005-12-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221605-A1 SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS PRKCA, PRKCB, PRKCE PRKCA 1/4885PRKCQ 12/4885PRKCB 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.